The stock has a 36-month beta value of 0.94. Opinions on the stock are mixed, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for BOLT is 24.14M, and at present, short sellers hold a 8.77% of that float. On May 24, 2024, the average trading volume of BOLT was 230.97K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
BOLT) stock’s latest price update
Bolt Biotherapeutics Inc (NASDAQ: BOLT) has experienced a rise in its stock price by 3.29 compared to its previous closing price of 0.77. However, the company has seen a gain of 0.90% in its stock price over the last five trading days. investorplace.com reported 2024-05-24 that Global stocks are surging. The MSCI ACWI Index, which encompasses both developed and emerging markets, reached another all-time high, continuing its record-breaking streak.
BOLT’s Market Performance
Bolt Biotherapeutics Inc (BOLT) has experienced a 0.90% rise in stock performance for the past week, with a -31.03% drop in the past month, and a -34.43% drop in the past quarter. The volatility ratio for the week is 5.33%, and the volatility levels for the past 30 days are at 7.03% for BOLT. The simple moving average for the last 20 days is -22.06% for BOLT’s stock, with a simple moving average of -26.45% for the last 200 days.
Analysts’ Opinion of BOLT
SVB Leerink, on the other hand, stated in their research note that they expect to see BOLT reach a price target of $36. The rating they have provided for BOLT stocks is “Outperform” according to the report published on March 02nd, 2021.
Stifel gave a rating of “Buy” to BOLT, setting the target price at $40 in the report published on March 02nd of the previous year.
BOLT Trading at -29.90% from the 50-Day Moving Average
After a stumble in the market that brought BOLT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -58.66% of loss for the given period.
Volatility was left at 7.03%, however, over the last 30 days, the volatility rate increased by 5.33%, as shares sank -27.94% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -27.28% lower at present.
During the last 5 trading sessions, BOLT rose by +0.88%, which changed the moving average for the period of 200-days by -37.51% in comparison to the 20-day moving average, which settled at $1.0109. In addition, Bolt Biotherapeutics Inc saw -28.57% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BOLT starting from Quinn William P., who purchase 7,500 shares at the price of $0.95 back on Dec 12 ’23. After this action, Quinn William P. now owns 36,272 shares of Bolt Biotherapeutics Inc, valued at $7,125 using the latest closing price.
Quinn William P., the Chief Financial Officer of Bolt Biotherapeutics Inc, purchase 2,500 shares at $0.78 during a trade that took place back on Dec 06 ’23, which means that Quinn William P. is holding 28,772 shares at $1,955 based on the most recent closing price.
Stock Fundamentals for BOLT
Current profitability levels for the company are sitting at:
- -6.61 for the present operating margin
- 0.77 for the gross margin
The net margin for Bolt Biotherapeutics Inc stands at -5.57. The total capital return value is set at -0.59. Equity return is now at value -48.14, with -36.11 for asset returns.
Based on Bolt Biotherapeutics Inc (BOLT), the company’s capital structure generated 0.16 points at debt to capital in total, while cash flow to debt ratio is standing at -3.21. The debt to equity ratio resting at 0.19. The interest coverage ratio of the stock is -52.18.
Currently, EBITDA for the company is -74.31 million with net debt to EBITDA at -0.21. When we switch over and look at the enterprise to sales, we see a ratio of 4.01. The receivables turnover for the company is 12.58for trailing twelve months and the total asset turnover is 0.08. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.68.
Conclusion
To sum up, Bolt Biotherapeutics Inc (BOLT) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
